Studies demonstrated that inhibition of the RAAS with ACE inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) may result in a compensatory increase in tissue levels of ACE2 and poorer clinical course and prognosis, leading to suggestions that these drugs may be detrimental to COVID-19 patients [14]. The gene discussed is ACE2; the disease is COVID-19.